摘要
目的 分析特利加压素联合恩替卡韦治疗乙型肝炎肝硬化失代偿期患者的临床效果。方法 回顾性对照研究,选取2020年1月起至2022年1月郑州大学第一附属医院收治的乙型肝炎肝硬化失代偿期100例患者,按治疗中用药不同将给予单独的恩替卡韦进行治疗的50例作为对照组,将恩替卡韦联合特利加压素治疗的50例作为观察组。结果 (1)治疗后观察组患者临床各项指标优于对照组,组间比较差异存在统计学意义(P<0.05);(2)观察组患者临床治疗总有效率高于对照组(P<0.05);(3)两组患者治疗后的肝功能均比治疗前有显著下降,观察组患者明显比对照组更低(P<0.05);(4)对照组患者治疗后出现的不良反应总体发生率较之于观察组显著增高(P<0.05);(5)治疗后两组患者炎症因子与治疗前比较显著降低,观察组低于对照组(P<0.05)。结论 将特利加压素以及恩替卡韦联合应用于乙肝肝硬化失代偿期患者的治疗中,有着显著的治疗效果,不仅能够促进患者肝功能得到改善,还能够有效抑制炎症因子,安全性较高,值得临床推广。
Objective To analyze clinical effect of terlipressin combined with entecavir in the treatment of patients with hepatitis B cirrhosis at decompensated stage.Methods A retrospective case-control study was conducted on 100 patients with decompensated hepatitis B cirrhosis admitted to Zhengzhou University Affiliated The First Hospital from January 2020 to January 2022.According to the different drugs in the treatment,50 patients were treated with entecavir alone as the control group,and 50 patients were treated with entecavir combined with terlipressin as the observation group.Results(1) After treatment,the clinical indicators of the control group were significantly better than those of the observation group,with statistically significant differences between the two groups(P<0.05).(2) The total effective rate of the observation group was significantly higher than that of control group(P<0.05).(3) The liver function of the two groups after treatment was significantly lower than that before treatment,and the liver function of control group was significantly lower than that of observation group(P<0.05).(4) The overall incidence of adverse reactions in the control group was higher than that in the observation group(P<0.05).(5) After treatment,the inflammatory factors of the two groups were significantly lower than those before treatment,and the inflammatory factors of observation group was lower than that of the group control(P<0.05).Conclusion Terlipressin combined with entecavir in the treatment of patients with decompensated hepatitis B cirrhosis has a significant therapeutic effect,which can not only promote the improvement of liver function,but also effectively inhibit inflammatory factors,with high safety,and is worthy of clinical promotion.
作者
叶青敏
王迪
史正艳
YE Qing-min;WANG Di;SHI Zheng-yan(Department of Hepatobiliary and Pancreatic Surgery,Zhengzhou University Affiliated The First Hospital,Zhengzhou 450052,China)
出处
《医药论坛杂志》
2023年第7期19-22,共4页
Journal of Medical Forum
基金
河南省2021年科技发展计划(212102310168)。
